Thor Medical ASA (OSL:TRMED)

Norway · Delayed Price · Currency is NOK

4.500

+0.045 (1.01%)

Oct 2, 2026, 4:25 PM CET

Market Cap	1.90B +53.2%
Revenue (ttm)	1.64M +1,539.0%
Net Income	-83.01M
EPS	-0.23
Shares Out	422.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,657,097
Open	4.495
Previous Close	4.455
Day's Range	4.405 - 4.570
52-Week Range	3.185 - 7.120
Beta	-0.01
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About Thor Medical ASA

Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It offers thorium-228, as well as radium-224 and lead-212 to radiopharmaceutical customers. The company was incorporated in 2009 and is headquartered in Oslo, Norway. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2009

Employees 24

Stock Exchange Oslo Børs

Ticker Symbol TRMED

Full Company Profile

Financial Performance

Financial Statements

News

Thor Medical ASA Earnings Call Transcript: H1 2026

AlphaOne is now operational, enabling first commercial deliveries and strong revenue visibility through NOK 850 million in sales agreements. H1 2026 saw NOK 900,000 in revenue and a negative EBITDA, but ramp-up is on track with EBITDA breakeven expected in 2027.

5 weeks ago - Transcripts

Thor Medical ASA Quarterly report: H1 2026

Thor Medical ASA has published its H1 2026 quarterly earnings report on August 28, 2026.

5 weeks ago - Filings

Thor Medical ASA Slides: H1 2026

Thor Medical ASA has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 28, 2026.

5 weeks ago - Filings

Thor Medical ASA Earnings Call Transcript: H2 2025

AlphaOne remains on track for completion and production ramp-up, supported by a NOK 850 million order backlog and strong market demand for alpha-emitting isotopes. The company is fully funded to reach cash-positive operations by 2027, with significant revenue potential and a growing customer base.

7 months ago - Transcripts